We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Phytopharm | LSE:PYM | London | Ordinary Share | GB00BCLY7L40 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 58.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Dec 2019 to Dec 2024
TIDMIXI
RNS Number : 0640B
IXICO plc
02 October 2015
2 October 2015
IXICO plc
(the 'Company')
Exercise of Share Options
IXICO plc ("IXICO" or the "Company")
Additional Listing
IXICO (AIM: IXI) announces that 142,581 new ordinary shares of 50 pence each in IXICO plc (the "New Ordinary Shares") have been issued and allotted pursuant to the exercise of options under the IXICO Technologies Limited Unapproved Share Option Scheme (the "Scheme"). Under the terms of the Scheme the new shares issued and allotted in IXICO Technologies Limited are subject to a put and call arrangement resulting in the New Ordinary Shares being issued and allotted.
Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 8 October 2015 and, when issued, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.
Following the admission to trading of the New Ordinary Shares, IXICO will have 15,201,563 ordinary shares of 50 pence each in issue.
Enquiries:
IXICO plc
Derek Hill, CEO
Susan Lowther, CFO
Charles Spicer, VP Corporate Development
+44 20 3763 7499
Peel Hunt LLP (Nominated Adviser and Broker)
James Steel
Oliver Jackson
+44 20 7418 8900+44 20 7418 8900
Daniel Stewart & Company (Joint Broker)
Mark Treharne
David Hart
+44 207 776 6550+44 207 776 6550
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISLLFLIISLFIIE
(END) Dow Jones Newswires
October 02, 2015 06:18 ET (10:18 GMT)
1 Year Phytopharm Chart |
1 Month Phytopharm Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
